Clinical value of alpha-fetoprotein heterogeneity 3, golgin 73 and glypican 3 in diagnosis of primary hepatic cancer / 肿瘤研究与临床

ABSTRACT

Objective To investigate the clinical value of serum tumor marker alpha-fetoprotein heterogeneity 3 (AFP-L3),golgin 73 (GP73) and glypican 3 (GPC-3) in primary hepatic cancer by ROC curve.Methods The AFP-L3,GP73,GPC-3 levels in serum were detected in 34 patients of primary hepatic cancer by enzyme immunoassay.Meanwhile,same terms from 20 healthy volunteers were detected as normal group.The area under curve was made by SPSS 17.0.Each laboratory indicator levels were compared and analyzed.Results The AFP-L3,GP73,GPC-3 levels in primary hepatic cancer group were significantly higher than those in normal control [(1890.13±506.47) ng/L vs (623.40±317.89) ng/L,(219.53±136.33) ng/ml vs (56.40± 25.63) ng/ml,(14.28±7.15) μg/L vs (7.33±3.71) μg/L,P ＜ 0.01].The areas under the concentration-time curve of receiver operating characteristic of single tumor marker were 0.909,0.832,0.817,the areas of AFP-L3+ GP73,AFP-L3+GPC-3,GP73+GPC-3 were 0.935,0.945,0.912,the area of combined detection of primaryhepatic cancer was 0.96.Conclusion AFP-L3 combines with GP73 and GPC-3 can increase the positive rate in patients with primary hepatic cancer and has important clinical significance.